Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives.
Ontology highlight
ABSTRACT: As one of the most potent osteoanabolic agents with a unique mechanism of action, romosozumab has high efficacy for osteoporosis treatment. It is a monoclonal antibody against sclerostin, a natural inhibitor of the Wnt signaling pathway, and by inhibiting sclerostin, activation of Wnt signaling occurs with a cascade of changes ultimately leading to bone mineral density (BMD) gains. Romosozumab stimulates bone modeling and has a dual effect of activating bone formation while inhibiting bone resorption. With this unique mechanism of action, treatment with romosozumab leads to a rapid and significant gain in BMD; these gains are higher than seen with bisphosphonates, denosumab, or parathyroid hormone (PTH) analogs. The FRAME and ARCH studies represent two pivotal trials demonstrating the effi
SUBMITTER: Lim SY
PROVIDER: S-EPMC9762257 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA